Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Phenylfentanyl is a synthetic opioid analgesic and a structural derivative of fentanyl. It was developed during research into potent opioid compounds, ultimately leading to the creation of super-potent analogues like carfentanil. Compared to fentanyl, 4‑Phenylfentanyl is approximately eight times more potent in animal analgesic tests. Like other fentanyl analogs, it acts primarily as an agonist at the mu-opioid receptor, producing strong pain relief but also significant risks such as respiratory depression and overdose. Its side effects are similar to those of other opioids and include itching, nausea, and potentially life-threatening respiratory depression[1][3][4]. The compound has no approved medical use and is considered illicit; it has been associated with fatalities in regions where novel synthetic opioids have emerged[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-phenylfentanyl.